CN112481284A - 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 - Google Patents
一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 Download PDFInfo
- Publication number
- CN112481284A CN112481284A CN202011431175.XA CN202011431175A CN112481284A CN 112481284 A CN112481284 A CN 112481284A CN 202011431175 A CN202011431175 A CN 202011431175A CN 112481284 A CN112481284 A CN 112481284A
- Authority
- CN
- China
- Prior art keywords
- mrna
- car
- seq
- cell
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 29
- 238000010276 construction Methods 0.000 title claims abstract description 14
- 229920002477 rna polymer Polymers 0.000 title abstract description 7
- 201000011510 cancer Diseases 0.000 title description 12
- 108090000623 proteins and genes Proteins 0.000 title description 5
- 239000002773 nucleotide Substances 0.000 claims abstract description 58
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 58
- 101150058049 car gene Proteins 0.000 claims abstract description 53
- 108090000695 Cytokines Proteins 0.000 claims abstract description 39
- 102000004127 Cytokines Human genes 0.000 claims abstract description 38
- 210000004027 cell Anatomy 0.000 claims description 127
- 239000003814 drug Substances 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims 21
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002147 killing effect Effects 0.000 abstract description 8
- 108700026220 vif Genes Proteins 0.000 abstract description 3
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 206010025323 Lymphomas Diseases 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 108010019160 Pancreatin Proteins 0.000 description 6
- 229940055695 pancreatin Drugs 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 229940088592 immunologic factor Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000367 immunologic factor Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101001010600 Homo sapiens Interleukin-12 subunit alpha Proteins 0.000 description 2
- 101000852992 Homo sapiens Interleukin-12 subunit beta Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
细胞名称 | 表达率 |
Seq1 | 35.29% |
Seq2KY | 38.02% |
Seq3YE | 37.00% |
Seq4 | 41.78% |
Seq4+5 | 38.08% |
Seq4+6 | 44.53% |
Seq4+7+8 | 45.31% |
Seq4+9 | 46.54 |
分组 | IFNγ(pg/ml) | 分组 | IFNγ(pg/ml) |
对照 | 105 | Seq4+5 | 411 |
Seq1 | 310 | Seq4+6 | 422 |
Seq2 | 336 | Seq4+7+8 | 440 |
Seq3 | 391 | Seq4+9 | 400 |
Seq4 | 382 |
对照 | Seq1 | Seq2 | Seq3 | Seq4 | Seq4+5 | Seq4+6 | Seq4+7+8 | Seq4+9 | |
INFγ | 0.65 | 27.55 | 30 | 25.5 | 32 | 34.6 | 37.1 | 37.5 | 42.5 |
TNFα | 0.35 | 1.5 | 1.3 | 1.15 | 1.5 | 1.6 | 1.35 | 1.4 | 1.55 |
IL2 | 3.65 | 71.5 | 77 | 79.2 | 78.8 | 78.5 | 81 | 81.3 | 86.4 |
对照 | Seq1 | Seq2 | Seq3 | Seq4 | Seq4+5 | Seq4+6 | Seq4+7+8 | Seq4+9 | |
INFγ | 0.5 | 2.6 | 3.05 | 1.4 | 2025 | 2.3 | 2.4 | 1.8 | 1.915 |
TNFα | 0.65 | 15 | 12.5 | 12 | 12.25 | 14 | 13.15 | 14.4 | 14.35 |
IL2 | 0.75 | 20.5 | 23.5 | 19 | 18.3 | 15.2 | 16 | 11.5 | 13 |
分组 | CAR-T比例 | 分组 | CAR-T比例 |
对照 | 0.4% | Seq4+5 | 19.1% |
Seq1 | 8.6% | Seq4+6 | 21.1% |
Seq2 | 11.3% | Seq4+7+8 | 25.75 |
Seq3 | 13.9% | Seq4+9 | 20.9% |
Seq4 | 14.45% |
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011431175.XA CN112481284B (zh) | 2020-12-07 | 2020-12-07 | 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 |
PCT/CN2020/137996 WO2022120934A1 (zh) | 2020-12-07 | 2020-12-21 | 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011431175.XA CN112481284B (zh) | 2020-12-07 | 2020-12-07 | 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112481284A true CN112481284A (zh) | 2021-03-12 |
CN112481284B CN112481284B (zh) | 2023-07-25 |
Family
ID=74940985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011431175.XA Active CN112481284B (zh) | 2020-12-07 | 2020-12-07 | 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112481284B (zh) |
WO (1) | WO2022120934A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023246938A1 (zh) * | 2022-06-24 | 2023-12-28 | 深圳瑞吉生物科技有限公司 | 用于实体肿瘤的治疗性mRNA及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107236762A (zh) * | 2017-06-19 | 2017-10-10 | 河北浓孚雨生物科技有限公司 | 一种微环dna转染t细胞制备临床级car‑t细胞制剂的方法 |
US20180125889A1 (en) * | 2015-04-15 | 2018-05-10 | Tc Biopharm Ltd | Modified gamma delta t cells and uses thereof |
CN108753773A (zh) * | 2018-05-03 | 2018-11-06 | 山东省齐鲁细胞治疗工程技术有限公司 | 干扰IFN-gama表达的CD19-CAR-T细胞及其应用 |
CN109055430A (zh) * | 2018-08-14 | 2018-12-21 | 杭州荣泽生物科技有限公司 | 一种共表达il18和ccl19蛋白及靶向muc1基因car-t细胞的制备方法 |
US20190040392A1 (en) * | 2016-04-21 | 2019-02-07 | Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet | Targeted mrna for in vivo application |
CN109504660A (zh) * | 2018-11-02 | 2019-03-22 | 温州启星生物技术有限公司 | 一种第四代car-t细胞及其构建方法和应用 |
CN110951695A (zh) * | 2019-12-31 | 2020-04-03 | 深圳市茵冠生物科技有限公司 | 通用型car-t细胞、其制备方法及其应用 |
CN111821433A (zh) * | 2020-02-06 | 2020-10-27 | 深圳市瑞吉生物科技有限公司 | mRNA疫苗及其合成方法、试剂盒 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL269270B (en) * | 2012-08-20 | 2022-07-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
SG11201508585PA (en) * | 2013-04-18 | 2015-11-27 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
DK3560953T3 (da) * | 2014-12-24 | 2024-04-02 | Autolus Ltd | Celle |
KR20180083874A (ko) * | 2015-11-04 | 2018-07-23 | 사울 제이. 프라이스맨 | Her2를 표적화하는 키메라 항원 수용체 |
-
2020
- 2020-12-07 CN CN202011431175.XA patent/CN112481284B/zh active Active
- 2020-12-21 WO PCT/CN2020/137996 patent/WO2022120934A1/zh unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180125889A1 (en) * | 2015-04-15 | 2018-05-10 | Tc Biopharm Ltd | Modified gamma delta t cells and uses thereof |
US20190040392A1 (en) * | 2016-04-21 | 2019-02-07 | Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet | Targeted mrna for in vivo application |
CN107236762A (zh) * | 2017-06-19 | 2017-10-10 | 河北浓孚雨生物科技有限公司 | 一种微环dna转染t细胞制备临床级car‑t细胞制剂的方法 |
CN108753773A (zh) * | 2018-05-03 | 2018-11-06 | 山东省齐鲁细胞治疗工程技术有限公司 | 干扰IFN-gama表达的CD19-CAR-T细胞及其应用 |
CN109055430A (zh) * | 2018-08-14 | 2018-12-21 | 杭州荣泽生物科技有限公司 | 一种共表达il18和ccl19蛋白及靶向muc1基因car-t细胞的制备方法 |
CN109504660A (zh) * | 2018-11-02 | 2019-03-22 | 温州启星生物技术有限公司 | 一种第四代car-t细胞及其构建方法和应用 |
CN110951695A (zh) * | 2019-12-31 | 2020-04-03 | 深圳市茵冠生物科技有限公司 | 通用型car-t细胞、其制备方法及其应用 |
CN111821433A (zh) * | 2020-02-06 | 2020-10-27 | 深圳市瑞吉生物科技有限公司 | mRNA疫苗及其合成方法、试剂盒 |
Non-Patent Citations (5)
Title |
---|
GENBANK: QHQ73567.1: "FMC63-CD828Z [synthetic construct]" * |
JENNIFER N. BRUDNO等: "Safety and feasibility of anti-CD19 CAR T cells with fully-human binding domains in patients with B-cell lymphoma" * |
MARGARET M BILLINGSLEY等: "Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering", 《NANO LETT》 * |
葛玉凤等: "CAR-T细胞治疗用于实体瘤的研究进展", 《转化医学电子杂志》 * |
蒲业迪等: "CD19 CAR-T细胞培养过程中PD-1蛋白、mRNA水平及细胞杀伤活性变化", 《中华血液学杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023246938A1 (zh) * | 2022-06-24 | 2023-12-28 | 深圳瑞吉生物科技有限公司 | 用于实体肿瘤的治疗性mRNA及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2022120934A1 (zh) | 2022-06-16 |
CN112481284B (zh) | 2023-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110734931A (zh) | 一种靶向CD19的人源化scFv嵌合抗原受体T细胞及制备方法、应用 | |
CN108409840A (zh) | 抗cd123单链抗体及其组合的嵌合抗原受体和应用 | |
CN108884440A (zh) | 用于增强免疫疗法的抗肿瘤活性的间充质干细胞 | |
CN108341881B (zh) | 带安全开关的嵌合抗原受体及其表达基因、其修饰的nk细胞及应用 | |
CN114230658B (zh) | 新型冠状病毒特异性t细胞受体和其用途 | |
CN105861531B (zh) | 一种嵌合抗原受体t细胞及其制备方法 | |
CN109265561B (zh) | 抗EGFRvⅢ安全型嵌合抗原受体、其制备方法、利用其修饰的NK细胞及应用 | |
US20220275337A1 (en) | Cellular compositions comprising viral vectors and methods of treatment | |
EA012520B1 (ru) | Способ получения цитотоксических лимфоцитов | |
CN112481284A (zh) | 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 | |
CN112266413A (zh) | 扩增nk细胞并增强其杀伤活性的因子、饲养细胞系及方法 | |
JP6687246B2 (ja) | 改変型免疫細胞、改変型免疫細胞の製造方法、およびこれらの利用 | |
CN116218790A (zh) | 分泌抗罗非鱼t淋巴细胞表面膜蛋白单克隆抗体的杂交瘤细胞株及其制备方法和应用 | |
JP2023548106A (ja) | 修飾された免疫細胞およびその用途 | |
WO2021036247A1 (zh) | 靶向Her2并干扰IL-6表达的嵌合抗原受体T细胞及其制备方法和应用 | |
CN105779480A (zh) | 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用 | |
CA2408756A1 (en) | Immune potentiating compositions | |
Weissinger et al. | Expression of HSV-TK suicide gene in primary T lymphocytes: the dog as a preclinical model | |
WO2022171179A1 (zh) | 一种扩增增强子及其应用 | |
CN116286666B (zh) | 滋养层细胞及其制备方法、应用和扩增nk细胞的方法 | |
Dessureault et al. | Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells | |
CN115960909A (zh) | 提高car-nk细胞阳性率的表达方法及ldl受体应用 | |
CN114891123A (zh) | 一种基于CD79b人源化抗体的嵌合抗原受体及其应用 | |
WO2022034506A1 (en) | Cellular compositions and methods of treatment | |
WO2023004461A1 (en) | Universal receptor immune cell therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40048813 Country of ref document: HK |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Hu Yong Inventor after: Zhang Miaomiao Inventor after: Hong Dan Inventor after: Hu Xun Inventor before: Zhang Miaomiao Inventor before: Hong Dan Inventor before: Hu Xun |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 518057 floor 4, building 2, Shenzhen biological incubation base, No. 10, Gaoxin Zhongyi Road, Maling community, Yuehai street, Nanshan District, Shenzhen, Guangdong Applicant after: Shenzhen Ruiji Biotechnology Co.,Ltd. Address before: 518064 a2-402, building a, Kexing Science Park, 15 Keyuan Road, Science Park community, Yuehai street, Nanshan District, Shenzhen City, Guangdong Province Applicant before: Shenzhen Ruiji Biotechnology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: CHRG Ref document number: 40066412 Country of ref document: HK Free format text: DELETION OF INVENTOR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: CHRG Ref document number: 40048813 Country of ref document: HK Free format text: ADDITION OF INVENTOR |